DEPARTMENT OF HEALTH & HUMAN SERVICES



MAY 2.7 7005

Food and Drug Adminis

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Public Health Service

Alcavis International, Incorporated % Mr. Gary J. Mishkin Vice President, Research and Development 8322 Helgerman Court Gaithersburg, Maryland 20877

Re: K082858

Trade/Device Name: ExSept WC Skin and Wound Cleanser

Regulation Number: 21 CFR 880.5475

Regulation Name: Jet Lavage

Regulatory Class: II Product Code: FQH Dated: April 17, 2009 Received: April 20, 2009

Dear Mr. Mishkin:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal</u> Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting

Page 2-Mr. Mishkin

(reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please contact the CDRH/Office of Surveillance and Biometrics/Division of Postmarket Surveillance at 240-276-3464. For more information regarding the reporting of adverse events, please go to http://www.fda.gov/cdrh/mdr/.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Mark N. Melkerson

Division of Surgical, Orthopedic

and Restorative Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

page 1 of 1

K082858 ExSept WC Skin and Wound Cleanser

Indications for Use

510(k) Number (if known):K082858					
Device Name: ExSept WC Skin and Wound Cleanser					
To 32 a 42 a a Villa VII a a					
Indications For Use:					
OTC: ExSept WC Skin and Wound Cleanser is intended for cleansing and removal of dirt, debris and foreign material from minor skin abrasions, minor lacerations, minor irritations, minor cuts, and intact skin.					
Professional Use: Under supervision of healthcare professionals, ExSept WC Skin and Wound Cleanser is intended for use for mechanical cleansing, debridement and removal of foreign material and debris from exudating and/or dirty wounds, such as stage I-IV pressure ulcers, diabetic foot ulcers, post surgical wounds, first and second degree burns, grafted and donor sites, and catheter exit sites.					
-					
Prescription Use X AND/OR Over-The-Counter Use X (Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)					
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IFNEEDED)					
Concurrence of CDRH, Office of Device Evaluation (ODE)					
Dail Krong la Mym					

(Division Sign-Off)
Division of Surgical, Orthopedic, and Restorative Devices

510(k) Number_K062656

Page **1** of **10**

1 450 1 0.

<u>Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links</u>

510(k) Premarket Notification



New Search Back To Search Results

Device Classification Name <u>Lavage, Jet</u> 510(K) Number K082858

Device Name EXSEPT WC ANTIMICROBIAL SKIN AND WOUND CLEANSER

ALCAVIS INTERNATIONAL, INC.

Applicant8322 Helgerman Court

Gaithersburg, MD 20877

ContactGary J MishkinRegulation Number880.5475Classification Product CodeFQHDate Received09/29/2008

Decision Date 05/27/2009

Decision Substantially Equivalent (SE)

Classification Advisory Committee General Hospital

Review Advisory Committee General & Plastic Surgery

Statement/Summary/Purged Status Summary Only

SummarySummaryTypeTraditional

Reviewed By Third Party No Expedited Review No